A series of 3,4-dihydro-3-amino-2H-1-benzopyran derivatives were prepared in order to determine the necessary structural requirements for good affinity for 5-HT1A receptors and high selectivity versus other receptors. Modifications of the extracyclic amino substituents, the length of the alkyl side chains, and their substituents were explored. The best compounds (9g, 9k, 15b, 15d) possess imido or sulfonamido functional groups with, a preferential length of four methylenes for the side chain. After resolution, the dextrorotatory enantiomers showed better affinity and selectivity for 5-HT1A receptors. These compounds have been proven to be full agonists. 9g and its enantiomers showed anxiolytic activity in vivo in various comportemental models. The compound (+)-9g is currently under clinical investigation.
US5314907A
申请人:——
公开号:US5314907A
公开(公告)日:1994-05-24
US5273994A
申请人:——
公开号:US5273994A
公开(公告)日:1993-12-28
US5346916A
申请人:——
公开号:US5346916A
公开(公告)日:1994-09-13
3-aminochroman compounds
申请人:Adir et Compagnie
公开号:US05510374A1
公开(公告)日:1996-04-23
The invention relates to compounds of the formula (I): ##STR1## in which: Z represents oxygen, R.sub.1 represents alkyl, R.sub.2 represents hydrogen or alkyl, n represents 1 through 6, R.sub.3 represents unsubstituted or substituted phenylacylamino, and antidepressive and other medicinal products containing the same.